Belatacept instead of tacrolimus for early kidney graft problems
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and had a kidney transplant from a living or deceased donor.
- Your blood types match in an allowed way for transplant (ABO-compatible) and the donor is not an exact HLA match.
- Your kidney function is reduced (creatinine clearance under 30 ml/min/1.73m²) based on the CKD-EPI estimate.
- Your 10-week post-transplant biopsy must show no rejection and no BK virus–related kidney damage, and no certain other damage problems.
- You must be Epstein-Barr virus (EBV) positive, and you must not have HIV.
- You must currently take CNI plus mycophenolate (MPA) with or without prednisone, and you must be able to understand and follow study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
Hear when a new Chronic Kidney Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.